News

Video

Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer

Author(s):

Bradley Monk, MD,Dana M. Chase, MD, FACOG

Key opinion leaders review recent updates to the NCCN guidelines for treating recurrent and advanced endometrial cancer, including biomarker testing and targeted therapies like dostarlimab and trastuzumab.

Related Videos
Kathleen N. Moore, MD, MS
Related Content
Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center
December 28th 2024

Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Lunresertib Plus Camonsertib in Endometrial, Ovarian Cancer | Image Credit: © Katsyarina - stock.adobe.com
December 19th 2024

Lunresertib Plus Camonsertib Produces Durable Responses in Advanced Endometrial, Ovarian Cancer

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Stephanie Gaillard, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
December 10th 2024

New ADCs Join NCCN Guidelines for Gynecologic Cancers Representing Step Forward

Monica H. Vetter, MD
December 5th 2024

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer